Right Brain Bio

Executive Summary

Right Brain Bio is a clinical-stage biotechnology company founded in 2020 and headquartered in San Francisco, California. The company is pioneering a novel, data-driven approach to treating Parkinson's disease based on a contrarian hypothesis about the disease's etiology. Its lead candidate, RB-190, has received FDA feedback and is poised to enter Phase 2 clinical trials. Despite being in early clinical stages with no disclosed funding rounds or valuation, the company's differentiated scientific premise and proximity to a Phase 2 milestone position it as an intriguing high-risk, high-reward opportunity in the neurodegenerative disease space. The contrarian nature of its hypothesis could either lead to transformative results or face significant skepticism.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Trial Initiation for RB-19080% success
• H1 2027Interim Safety and Efficacy Data from Phase 245% success
• Q4 2026Series A or B Financing Round60% success